Jan 31, 2022
PBS listed Calquence for non-Hodgkin lymphoma
Australia included Calquence (acalabrutinib) for mantle cell lymphoma, a form of non-Hodgkin lymphoma. Mantle cell lymphoma is a relatively new form of non-Hodgkin lymphoma.
The Australians could access the script for $42.50 or $6.80 with a concession card; without coverage, the patient might need to spend $8,200 per script.
Braftovi was included in the PBS in Australia for bowel cancer
The Australian government has announced that it has included Braftovi (encorafenib) in the Pharmaceutical Benefits Scheme for bowel cancer. Braftovi is available for treating BRAF V600 metastatic colorectal cancer.
As per the government, colorectal cancer is the third most cancer, and nearly 15,500 new cases are diagnosed each year.
BRAF mutation accounts for 10% of colorectal cancers. The drug is administered in combination with cetuximab. The combination can stop cancer growth, help patients survive, and improve their quality of life.
The maximum co-payment is $42.50 and $6.80 for concession card-holders. The safety threshold for concession card holders is $326.40; medicines will be provided free of charge once the patients reach the safety net threshold.
The recommendation is based on the opinion of Pharmaceutical Benefits Advisory Committee experts.
For pipeline, market overview, and market access reports (syndicate and customized) please write to sales@firstviewinsight.com
For all syndicate reports: Click here